Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5944
    +0.0007 (+0.11%)
     

  • NZD/EUR

    0.5547
    +0.0001 (+0.02%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.90
    +0.09 (+0.11%)
     

  • GOLD

    2,325.20
    -13.20 (-0.56%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,295.93
    +94.66 (+0.55%)
     

  • NIKKEI 225

    37,708.95
    -751.13 (-1.95%)
     

  • NZD/JPY

    92.3990
    +0.2840 (+0.31%)
     

Why Alzamend Neuro Stock Soared Today

Joe Tenebruso, The Motley Fool
·1-min read
Why Alzamend Neuro Stock Soared Today

Shares of Alzamend Neuro (NASDAQ: ALZN) surged 28% on Tuesday, as investors bought in ahead of the biotech's upcoming clinical data release for its experimental Alzheimer's treatment. Alzamend is an early stage biopharmaceutical company focused on creating therapies for neurodegenerative diseases and psychiatric conditions. Its investigational oral treatment for dementia related to Alzheimer's, AL001, has been shown to prevent cognitive impairment in mice. Alzamend is currently conducting a phase 1 human clinical study to evaluate the safety and proper dosing for AL001 in a planned phase 2 trial.

Continue reading